Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market by Scale of Operation, Type of Vector, Application Area, Therapeutic Area, and Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

With the increasing number of cell and gene therapies being developed and launched for a wide range of therapeutic areas, these modalities are on their way to become one of the highest valued markets in the biopharmaceutical domain. In fact, in 2021, cell and gene therapy developers raised capital worth more than USD 20 billion, registering an increase of 19% from the amount raised in 2020 (~USD 17 billion). It is worth highlighting that, in February 2022, the USFDA approved second CAR-T therapy, CARVYKTI™, developed by Johnson and Johnson, which can be used for the treatment of relapsed or refractory multiple myeloma. Additionally, close to 1,500 clinical trials are being conducted, globally, for the evaluation of cell and gene therapies. Over time, it has been observed that the clinical success of these therapies relies on the design and type of gene delivery vector used (in therapy development and / or administration). At present, several innovator companies are actively engaged in the development / production of viral vectors and / or non-viral vectors for cell and gene therapies. In this context, it is worth mentioning that, over the past few years, multiple viral vector and non-viral vector based vaccine candidates have been developed against COVID-19 (caused by novel coronavirus, SARS-CoV-2) and oncological disorders; this is indicative of lucrative opportunities for companies that have the required capabilities for viral vector manufacturing and gene therapy manufacturing.

The viral vector manufacturing and non-viral vector manufacturing landscape features a mix of industry players (well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. It is worth highlighting that several companies that have the required capabilities and facilities to manufacture vectors for both in-house requirements and offer contract services (primarily to ensure the optimum use of their resources and open up additional revenue generation opportunities) have emerged in this domain. Further, in order to produce more effective and affordable vectors, several stakeholders are integrating various novel technologies; these technologies are likely to improve the scalability and quality of the resultant therapy. In addition, this industry has also witnessed a significant increase in the partnership and expansion activities over the past few years, with several companies having been acquired by the larger firms. Given the growing demand for interventions that require genetic modification, the vector and gene therapy manufacturing market is poised to witness substantial growth in the foreseen future.

Scope of the Report

The “Viral Vector Manufacturing, Non-Viral Vector Manufacturing and Gene Therapy Manufacturing Market (5th Edition) by Scale of Operation (Preclinical, Clinical and Commercial), Type of Vector (AAV Vector, Adenoviral Vector, Lentiviral Vector, Retroviral Vector, Plasmid DNA and Others), Application Area (Gene Therapy, Cell Therapy and Vaccine), Therapeutic Area (Oncological Disorders, Rare Disorders, Neurological Disorders, Sensory Disorders, Metabolic Disorders, Musco-skeletal Disorders, Blood Disorders, Immunological Diseases, and Others), and Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the rapidly growing market of vector and gene therapy manufacturing, focusing on contract manufacturers, as well as companies having in-house manufacturing facilities. The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different regions of the globe.

Amongst other elements, the report includes:

An overview of the current status of the market with respect to the players engaged (both industry and non-industry) in the manufacturing of viral, non-viral and other novel types of vectors and gene therapies. It features information on the year of establishment, company size, location of headquarters, type of product manufactured (vector and gene therapy / cell therapy / vaccine), location of manufacturing facilities, type of manufacturers (in-house and contract services), scale of operation (preclinical, clinical and commercial), type of vector manufactured (AAV, adenoviral, lentiviral, retroviral, plasmid DNA and others) and application area (gene therapy, cell therapy, vaccine and others).
An analysis of the technologies offered / developed by the companies enagaged in this domain, based on the type of technology (viral vector manufacturing related platform, non-viral vector manufacturing related platform and others), type of manufacturer (vector manufacturing, gene delivery, product manufacturing, transduction / transfection, vector packaging and other), scale of operation (preclinical, clinical and commercial), type of vector involved (AAV, adenoviral, lentiviral, retroviral, non-viral and other viral vectors), application area (gene therapy, cell therapy, vaccine and others). It also highlights the most prominent players within this domain, in terms of number of technologies.
A region-wise, company competitiveness analysis, highlighting key players engaged in the manufacturing of vectors and gene therapies, across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (based on experience in this field), manufacturing strength (type of product manufactured, number of manufacturing facilites and number of application areas), service strength (scale of operation, number of vectors manufactured and geographical reach) and company size (small, mid-sized and large).
Elaborate profiles of key players based in North America, Europe and Asia-Pacific (shortlisted based on proprietary criterion). Each profile features an overview of the company / organization, its financial performance (if available), information related to its manufacturing facilities, vector manufacturing technology and an informed future outlook.
Tabulated profiles of the other key players headquartered in different regions across the globe (shortlisted based on proprietary criterion). Each profile features an overview of the company, its financial performance (if available), information related to its manufacturing capabilities, and an informed future outlook.
An analysis of partnerships and collaborations established in this domain since 2015; it includes details of deals that were / are focused on the manufacturing of vectors, which were analyzed on the basis of year of partnership, type of partnership (manufacturing agreement, product / technology licensing, product development, merger / acqusition, research and development agreement, process development / optimization, service alliance, production asset / facility acquisition, supply agreement and others), scale of operation (preclinical, clinical and commercial), type of vector involved (AAV, adenoviral, lentiviral, retroviral, plasmid and others), region and most active players (in terms of number of partnerships).
An analysis of the expansions related to viral vector manufacturing and non-viral vector manufacturing, which have been undertaken since 2015, based on several parameters, such as year of expansion, type of expansion (new facility / plant establishment, facility expansion, technology installation / expansion, capacity expansion, service expansion and others), type of vector (AAV, adenoviral, lentiviral, retroviral, plasmid and others), application area (gene therapy, cell therapy, vaccine and others) and geographical location of the expansion.
An analysis evaluating the potential strategic partners (comparing vector based therapy developers and vector purification product developers) for vector and gene therapy product manufacturers, based on several parameters, such as developer strength, product strength, type of vector, therapeutic area, pipeline strength (preclinical and clinical).
An overview of other viral / non-viral gene delivery approaches that are currently being researched for the development of therapies involving genetic modification.
An in-depth analysis of viral vector manufacturers and plasmid DNA manufacturers, featuring three schematic representations, a three dimensional grid analysis, representing the distribution of vector manufacturers (on the basis of type of vector) across various scales of operation and type of manufacturer (in-house operations and contract manufacturing services), a heat map of viral vector manufacturers and plasmid DNA manufacturers based on the type of vector (AAV, adenoviral vector, lentiviral vector, retroviral vector and plasmid DNA) and type of organization (industry (small, mid-sized and large) and non-industry), and a schematic world map representation, highlighting the headquarters and geographical location of key vector manufacturing hubs.
An analysis of the various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of proprietary vectors.
An estimate of the overall, installed vector manufacturing capacity of industry players based on the information available in the public domain, and insights generated via both secondary and primary research. The analysis also highlights the distribution of the global capacity by company size (small, mid-sized and large), scale of operation (clinical and commercial), type of vector (viral vector and plasmid DNA) and region (North America, Europe, Asia Pacific and the rest of the world).
An informed estimate of the annual demand for viral and non-viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength.
A discussion on the factors driving the market and various challenges associated with the vector production process.
A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of drug developers, bargaining power of vector and gene therapy manufacturers, threats of substitute technologies and rivalry among existing competitors.

One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the vector and gene therapy manufacturing market, over the coming decade. Based on various parameters, such as the likely increase in number of clinical studies, anticipated growth in target patient population, existing price variations across different types of vectors, and the anticipated success of gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. In order to provide a detailed future outlook, our projections have been segmented on the basis of scale of operation (preclinical, clinical and commercial), type of vector (AAV vector, adenoviral vector, lentiviral vector, retroviral vector, plasmid DNA and others), application area (gene therapy, cell therapy and vaccine), therapeutic area (oncological disorders, rare disorders, neurological disorders, sensory disorders, metabolic disorders, musco-skeletal disorders, blood disorders, immunological diseases, and others) and geographical region (North America, Europe, Asia Pacific, MENA, Latin America and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights generated from both secondary and primary research. For the purpose of the study, we invited over 300 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:

Menzo Havenga (Chief Executive Officer and President, Batavia Biosciences)
Nicole Faust (Chief Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
Cedric Szpirer (Former Executive & Scientific Director, Delphi Genetics)
Olivier Boisteau, (Co-Founder / President, Clean Cells), Laurent Ciavatti (Former Business Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy, Clean Cells)
Alain Lamproye (Former President of Biopharma Business Unit, Novasep)
Joost van den Berg (Former Director, Amsterdam BioTherapeutics Unit)
Bakhos A Tannous (Director, MGH Viral Vector Development Facility, Massachusetts General Hospital)
Eduard Ayuso, DVM, PhD (Scientific Director, Translational Vector Core, University of Nantes)
Colin Lee Novick (Managing Director, CJ Partners)
Semyon Rubinchik (Scientific Director, ACGT)
Astrid Brammer (Senior Manager Business Development, Richter-Helm)
Marco Schmeer (Project Manager, Plasmid Factory) and Tatjana Buchholz (Former Marketing Manager, Plasmid Factory)
Brain M Dattilo (Business Development Manager, Waisman Biomanufacturing)
Beatrice Araud (ATMP Key Account Manager, EFS-West Biotherapy)
Nicolas Grandchamp (R&D Leader, GEG Tech)
Géraldine Guérin-Peyrou (Director of Marketing and Technical Support, Polypus Transfection)
Naiara Tejados, Head of Marketing and Technology Development, VIVEBiotech)
Jeffery Hung (Independent Consultant)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

Who are the leading players (contract service providers and in-house manufacturers) engaged in the development of vectors and gene therapies?
Which regions are the current manufacturing hubs for vectors and gene therapies?
Which type of vector related technologies are presently offered / being developed by the stakeholders engaged in this domain?
Which companies are likely to partner with viral vector manufacturing and non-viral vector manufacturing service providers?
Which partnership models are commonly adopted by stakeholders engaged in this industry?
What type of expansion initiatives are being undertaken by players in this domain?
What are the various emerging viral and non-viral vectors used by players for the manufacturing of genetically modified therapies?
What are the strengths and threats for the stakeholders engaged in this industry?
What is the current, global demand for viral and non-viral vector, and gene therapies?
How is the current and future market opportunity likely to be distributed across key market segments?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Viral and Non-Viral Gene Transfer Techniques
3.3. Viral Vectors Used in Genetically Modified Therapies
3.4. Types of Viral Vectors
3.4.1. Adeno-associated Viral Vectors
3.4.2. Adenoviral Vectors
3.4.3. Lentiviral Vectors
3.4.4. Retroviral Vectors
3.4.5. Other Viral Vectors
3.4.5.1. Alphavirus
3.4.5.2. Foamy Virus
3.4.5.3. Herpes Simplex Virus
3.4.5.4. Sendai Virus
3.4.5.5. Simian Virus
3.4.5.6. Vaccinia Virus
3.5. Types of Non-Viral Vectors
3.5.1. Plasmid DNA
3.5.2. Liposomes, Lipoplexes and Polyplexes
3.5.3. Oligonucleotides
3.5.4. Other Non-Viral Vectors
3.6. Gene Delivery using Non-Viral Vectors
3.6.1. Biolistic Methods
3.6.2. Electroporation
3.6.3. Receptor Mediated Gene Delivery
3.6.4. Gene Activated Matrix (GAM)
3.7. Applications of Viral and Non-Viral Vectors
3.7.1. Type of Therapy
3.7.1.1. Cell and Gene Therapy
3.7.1.2. Vaccinology
3.8. Current / Ongoing Trends in Vector Development / Manufacturing
3.8.1. Vector Engineering
3.8.2. Cargo Engineering
3.9. Vector Manufacturing
3.9.1. Types of Vector Manufacturers
3.9.2. Viral Vector Manufacturing Processes
3.9.2.1 Vector Production
3.9.2.2. Adherent and Suspension Cultures
3.9.2.3. Unit Process Versus Multiple Parallel Processes
3.9.2.4. Cell Culture Systems for Production of Viral Vectors
3.9.2.5. Serum-Containing versus Serum-Free Media
3.9.3. Bioprocessing of Viral Vectors
3.9.3.1. AAV Vector Production
3.9.3.2. Adenoviral Vector Production
3.9.3.3. Lentiviral Vector Production
3.9.3.4. ? -Retroviral Vector Production
3.9.4. Key Challenges Associated with Vector Manufacturing
3.10. Future Perspectives

4. VIRAL VECTOR AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Viral Vector and Gene Therapy Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Product Manufactured
4.2.5. Analysis by Location of Vector Manufacturing Facilities
4.2.6. Analysis by Type of Manufacturer
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Location of Headquarters and Scale of Operation
4.2.9. Analysis by Type of Vector Manufactured
4.2.10. Analysis by Scale of Operation and Type of Vector Manufactured
4.2.11. Analysis by Application Area
4.2.12. Information on Production Capacity

5. PLASMID DNA AND GENE THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

5.1. Chapter Overview
5.2. Plasmid DNA and Gene Therapy Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Heat Map: Analysis by Company Size and Location of Headquarters
5.2.5. Analysis by Type of Product Manufactured
5.2.6. Analysis by Location of Plasmid DNA Manufacturing Facilities
5.2.7. Analysis by Type of Manufacturer
5.2.8. Analysis by Scale of Operation
5.2.9. Analysis by Application Area
5.2.10. Information on Production Capacity

6. VECTOR AND GENE THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Vector and Gene Therapy Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Location of Vector Manufacturing Facilities
6.2.3. Analysis by Type of Manufacturer
6.2.4. Analysis by Scale of Operation
6.2.5. Analysis by Type of Vector Manufactured
6.2.6. Analysis by Scale of Operation and Type of Vector Manufactured
6.2.7. Analysis by Application Area

7. VECTOR AND GENE THERAPY MANUFACTURING TECHNOLOGIES: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Vector and Gene Therapy Manufacturing Technologies
7.2.1. Analysis by Type of Technology
7.2.2. Analysis by Purpose of Technology
7.2.3. Analysis by Scale of Operation
7.2.4. Analysis by Type of Vector
7.2.5. Analysis by Application Area
7.2.6. Most Active Players: Analysis by Number of Technology
7.3. Concluding Remarks

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Vector and Gene Therapy: In-House Manufacturers
8.3.1. Players based in North America
8.3.2. Players based in Europe
8.3.3. Players based in Asia-Pacific and Rest of the World
8.4. Vector and Gene Therapy: Contract Manufacturing Organizations
8.4.1. Players based in North America
8.4.2. Players based in Europe
8.4.3. Players based in Asia-Pacific and Rest of the World
8.5. Vector and Gene Therapy: Players Engaged in In-house and Contract Manufacturing
8.5.1. Players based in North America
8.5.2. Players based in Europe
8.5.3. Players based in Asia-Pacific and Rest of the World

9. VECTOR AND GENE THERAPY MANUFACTURERS IN NORTH AMERICA

9.1. Chapter Overview
9.2. Advanced BioScience Laboratories
9.2.1. Company Overview
9.2.2. Manufacturing Facilities
9.2.3. Recent Developments and Future Outlook
9.3. Aldevron
9.3.1. Company Overview
9.3.2. Financial Information
9.3.3. Manufacturing Facilities
9.3.4. Manufacturing Experience
9.3.5. Recent Developments and Future Outlook
9.4. BioReliance / SAFC Commercial (Merck KGaA)
9.4.1. Company Overview
9.4.2. Financial Information
9.4.3. Vector Manufacturing Technology Portfolio
9.4.4. Manufacturing Facilities
9.4.5. Recent Developments and Future Outlook
9.5. bluebird bio
9.5.1. Company Overview
9.5.2. Financial Information
9.5.3. Manufacturing Facilities
9.5.4. Manufacturing Experience
9.5.5. Recent Development and Future Outlook
9.6. Other Companies
9.6.1. Audentes Therapeutics
9.6.1.1. Company Overview
9.6.1.2. Financial Information
9.6.1.3. Manufacturing Facilities
9.6.1.4. Recent Developments and Future Outlook
9.6.2. Emergent BioSolutions
9.6.2.1. Company Overview
9.6.2.2. Financial Information
9.6.2.3 Manufacturing Facilities
9.6.2.4. Recent Developments and Future Outlook
9.6.3. FUJIFILM Diosynth Biotechnologies
9.6.3.1. Company Overview
9.6.3.2. Financial Information
9.6.3.3. Manufacturing Facilities
9.6.3.4. Manufacturing Experience
9.6.3.5. Recent Developments and Future Outlook
9.6.4. MeiraGTx
9.6.4.1. Company Overview
9.6.4.2. Manufacturing Facilities
9.6.4.3. Recent Developments and Future Outlook
9.6.5. Spark Therapeutics
9.6.5.1. Company Overview
9.6.5.2. Financial Information
9.6.5.3. Manufacturing Facilities
9.6.5.4. Vector Manufacturing Technology Portfolio
9.6.5.5. Manufacturing Experience
9.6.5.6. Recent Developments and Future Outlook
9.6.7. Vigene Biosciences
9.6.7.1. Company Overview
9.6.7.2. Manufacturing Facilities
9.6.7.3. Vector Manufacturing Technology Portfolio
9.6.7.4. Manufacturing Experience
9.6.7.5. Recent Developments and Future Outlook

10. VECTOR AND GENE THERAPY MANUFACTURERS IN EUROPE

10.1. Chapter Overview
10.2. Biovian
10.2.1. Company Overview
10.2.2. Manufacturing Facilities
10.2.3. Recent Developments and Future Outlook
10.3. Centre for Process Innovation
10.3.1. Company Overview
10.3.2. Manufacturing Facilities
10.3.3. Recent Developments and Future Outlook
10.4. Cobra Biologics
10.4.1. Company Overview
10.4.2. Financial Information
10.4.3. Manufacturing Facilities
10.4.4. Vector Manufacturing Technology Portfolio
10.4.5. Manufacturing Experience
10.4.6. Recent Developments and Future Outlook
10.5. FinVector
10.5.1. Company Overview
10.5.2. Manufacturing Facilities
10.5.3. Vector Manufacturing Technology Portfolio
10.5.4. Manufacturing Experience
10.5.5. Recent Developments and Future Outlook
10.6. Kaneka Eurogentec
10.6.1. Company Overview
10.6.2. Manufacturing Facilities
10.6.3. Manufacturing Experience
10.6.4. Recent Developments and Future Outlook
10.7. Lonza
10.7.1. Company Overview
10.7.2. Financial Information
10.7.3. Vector Manufacturing Technology Portfolio
10.7.4. Manufacturing Facilities
10.7.5. Recent Developments and Future Outlook
10.8. MolMed
10.8.1. Company Overview
10.8.2. Financial Information
10.8.3. Manufacturing Facilities
10.8.4. Recent Developments and Future Outlook
10.9. Novasep
10.9.1. Company Overview
10.9.2. Financial Information
10.9.3. Manufacturing Facilities
10.9.4. Manufacturing Experience
10.9.5. Recent Developments and Future Outlook
10.10. Orchard Therapeutics
10.10.1. Company Overview
10.10.2. Manufacturing Facilities
10.10.3 Recent Developments and Future Outlook
10.11. Oxford BioMedica
10.11.1. Company Overview
10.11.2. Financial Information
10.11.3. Manufacturing Facilities
10.11.4. Vector Manufacturing Technology Portfolio
10.11.5. Manufacturing Experience
10.11.6. Recent Developments and Future Outlook
10.12. Richter-Helm
10.12.1. Company Overview
10.12.2. Manufacturing Facilities
10.12.3. Recent Developments and Future Outlook
10.13. Sanofi (CEPiA, Sanofi Pasteur, Genzyme)
10.13.1. Company Overview
10.13.2. Financial Information
10.13.3. Manufacturing Facilities
10.13.4. Recent Developments and Future Outlook
10.14. uniQure
10.14.1. Company Overview
10.14.2. Financial Information
10.14.3. Manufacturing Facilities
10.14.4. Vector Manufacturing Technology Portfolio
10.14.5. Recent Developments and Future Outlook
10.15. Vibalogics
10.15.1. Company Overview
10.15.2. Manufacturing Facilities
10.15.3. Recent Developments and Future Outlook
10.16. VIVEbiotech
10.16.1. Company Overview
10.16.2. Vector Manufacturing Technology Portfolio
10.16.3. Manufacturing Facilities
10.16.4. Recent Developments and Future Outlook
10.17. Other Companies
10.17.1. Cell and Gene Therapy Catapult
10.17.1.1. Company Overview
10.17.1.2. Manufacturing Facilities
10.17.1.3. Recent Developments and Future Outlook

11. VECTOR AND GENE THERAPY MANUFACTURERS IN ASIA-PACIFIC

11.1. Chapter Overview
11.2. Wuxi AppTec
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Manufacturing Facilities
11.2.4. Manufacturing Experience
11.2.5. Recent Developments and Future Outlook
11.3. Other Key Players

12. OTHER KEY PLAYERS

12.1. Chapter Overview
12.2. Thermo Fisher Scientific
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Vector Manufacturing Related Capabilities
12.2.4. Recent Developments and Future Outlook
12.3. BioNTech Innovative Manufacturing
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Vector Manufacturing Related Capabilities
12.3.4. Recent Developments and Future Outlook
12.3. Celonic
12.3.1. Company Overview
12.3.2. Vector Manufacturing Related Capabilities
12.3.3. Recent Developments and Future Outlook

13. RECENT PARTNERSHIPS

13.1. Chapter Overview
13.2. Partnership Models
13.3. Vector and Gene Therapy Manufacturing: Recent Partnerships
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Scale of Operation
13.3.4. Analysis by Type of Vector
13.3.5. Analysis by Therapeutic Area
13.3.6. Most Active Players: Analysis by Number of Partnerships
13.3.7. Geographical Analysis
13.3.7.1. Intercontinental and Intracontinental Agreements
13.4. Other Collaborations

14. RECENT EXPANSIONS

14.1. Chapter Overview
14.2. Expansions Models
14.3. Vector and Gene Therapy Manufacturing: Recent Expansions
14.3.1. Analysis by Year of Expansion
14.3.2. Analysis by Type of Expansion
14.3.3. Analysis by Amount Invested by Key Players
14.3.4. Analysis by Scale of Operation
14.3.5. Analysis by Type of Vector
14.3.6. Analysis by Application Area
14.3.7. Most Active Players: Analysis by Number of Expansions
14.3.8. Geographical Analysis
14.3.8.1. Analysis by Location of Expansion

15. STRATEGIC PARTNER ANALYSIS

15.1. Chapter Overview
15.2. Strategic Partner Analysis: Viral Vector based Therapy Developers
15.3. Methodology and Key Parameters
15.3.1. Opportunities for AAV Vector- based Therapy Developers
15.3.1.1. Most Likely Partners
15.3.1.2. Likely Partners
15.3.1.3. Less Likely Partners
15.3.1.4. Least Likely Partners
15.3.2. Opportunities for Adenoviral Vector based Therapy Developers
15.3.2.1. Most Likely Partners
15.3.2.2. Likely Partners
15.3.2.3. Less Likely Partners
15.3.2.4. Least Likely Partners
15.3.3. Opportunities for Lentiviral Vector based Therapy Developers
15.3.3.1. Most Likely Partners
15.3.3.2. Likely Partners
15.3.3.3. Less Likely Partners
15.3.3.4. Least Likely Partners
15.3.4. Opportunities for Retroviral Vector based Therapy Developers
15.3.4.1. Most Likely Partners
15.3.4.2. Likely Partners
15.3.4.3. Less Likely Partners
15.3.4.4. Least Likely Partners
15.3.5. Opportunities for Other Viral Vector based Therapy Developers
15.3.5.1. Most Likely Partners
15.3.5.2. Likely Partners
15.3.5.3. Less Likely Partners
15.3.5.4. Least Likely Partners
15.4. Strategic Partner Analysis: Viral Vector based Purification Product Developers
15.5. Methodology and Key Parameters
15.5.1. Opportunities for AAV based Purification Product Developers
15.5.1.1. Most Likely Partners
15.5.1.2. Likely Partners
15.5.2. Opportunities for Adenoviral Vector based Purification Product Developers
15.5.2.1. Most Likely Partners
15.5.2.2. Likely Partners
15.5.3. Opportunities for Lentiviral Vector based Purification Product Developers
15.5.3.1. Most Likely Partners
15.5.3.2. Likely Partners
15.5.4. Opportunities for Retroviral Vector based Purification Product Developers
15.5.4.1. Most Likely Partners
15.5.4.2. Likely Partners
15.5.5. Opportunities for Other Viral Vector based Purification Product Developers
15.5.5.1. Most Likely Partners
15.5.5.2. Likely Partners

16. EMERGING VECTORS

16.1. Chapter Overview
16.1.1. Alphavirus based Vectors
16.1.2. Anc80 based Vectors
16.1.3. Bifidobacterium longum based Vectors
16.1.4. Cytomegalovirus based Vectors
16.1.5. Listeria monocytogenes based Vectors
16.1.6. Minicircle DNA based Vectors
16.1.7. Myxoma Virus based Vectors
16.1.8. Self-Complementary Vectors
16.1.9. Sendai Virus based Vectors
16.1.10. Sleeping Beauty Transposons
16.1.11. Vaccinia Virus and Modified Vaccinia Ankara based Vectors
16.1.12. Chimeric Viral Vectors

17. KEY INSIGHTS

17.1. Chapter Overview
17.2. Vector and Gene Therapy Manufacturers: Analysis by Purpose of Manufacturing, Type of Vector Manufactured and Scale of Operation
17.3. Vector and Gene Therapy Manufacturers: Analysis by Company Size and Type of Vector Manufactured
17.4. Vector and Gene Therapy Manufacturers: Prominent Geographical Hubs by Type of Organization
17.4.1. Contract Manufacturing Organizations
17.4.2. In-House Manufacturers
17.5. Vector and Gene Therapy Manufacturers: Analysis by Location of Manufacturing Facilities and Type of Vector Manufactured
17.5.1. AAV Vector Manufacturers
17.5.2. Adenoviral Vector Manufacturers
17.5.3. Lentiviral Vector Manufacturers
17.5.4. Retroviral Vector Manufacturers
17.5.5. Plasmid DNA Manufacturers

18. COST PRICE ANALYSIS

18.1. Chapter Overview
18.2. Factors Contributing to High Price of Viral Vector and Plasmid DNA based Therapies
18.3. Viral Vector and Plasmid DNA based Therapies: Pricing Models
18.3.1. Pricing Models on the Basis of Expert Opinions
18.3.2. Pricing Models on the Basis of Manufacturing Cost
18.3.2.1. Pricing Models on the Basis of Technology Used
18.3.2.2. Pricing Models on the Basis of Scale of Manufacturing
18.3.2.3. Pricing Models on the Basis of Type of Client
18.3.3. Prices of Different Types of Vectors
18.4. Concluding Remarks

19. CAPACITY ANALYSIS

19.1. Chapter Overview
19.2. Methodology and Key Assumptions
19.2. Global Installed Viral Vector and Gene Therapy Manufacturing Capacity
19.3. Global Installed Viral Vector Manufacturing Capacity
19.3.1. Analysis by Company Size
19.3.2. Analysis by Scale of Operation
19.3.3. Analysis by Location of Manufacturing Facilities
19.4. Global Installed Plasmid DNA Manufacturing Capacity
19.4.1. Analysis by Company Size
19.4.2. Analysis by Scale of Operation
19.4.3. Analysis by Location of Manufacturing Facilities
19.4. Concluding Remarks

20. DEMAND ANALYSIS

20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Global Clinical Demand for Viral Vectors and Plasmid DNA, 2022-2035
20.3.1. Analysis by Type of Vector
20.3.2. Analysis by Type of Therapy
20.3.3. Analysis by Therapeutic Area
20.3.4. Analysis by Geographical Location
20.4. Global Commercial Demand for Viral Vectors and Plasmid DNA, 2022-2035
20.4.1. Analysis by Type of Vector
20.4.2. Analysis by Type of Therapy
20.4.3. Analysis by Therapeutic Area
20.4.4. Analysis by Geographical Location
20.5. Demand and Supply Analysis
20.5.1. Scenario 1
20.5.2. Scenario 2
20.5.3. Scenario 3

21. MARKET SIZING AND OPPORTUNITY ANALYSIS

21.1. Chapter Overview
21.2. Scope of the Forecast
21.3. Forecast Methodology
21.4. Input Tables and Key Assumptions
21.5. Global Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035
21.5.1. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Type of Vector Manufactured
21.5.1.1. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Market Attractiveness by Purpose of Manufacturing
21.5.2. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Scale of Operation
21.5.3. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Type of Vector Manufactured
21.5.4. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Therapeutic Area
21.5.5. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Application Area
21.5.6. Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035: Distribution by Key Geographical Regions
21.6. Current and Future Market Opportunity for Commercial Products
21.6.1. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2022-2035: Distribution by Type of Vector Manufactured
21.6.1.1. AAV Vectors
21.6.1.1.1. AAV Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.1.2. AAV Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.1.3. AAV Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.1.2. Adenoviral Vectors
21.6.1.2.1. Adenoviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.2.2. Adenoviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.2.3. Adenoviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.1.3. Lentiviral Vectors
21.6.1.3.1. Lentiviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.3.2. Lentiviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.3.3. Lentiviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.1.4. Retroviral Vectors
21.6.1.4.1. Retroviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.4.2. Retroviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.4.3. Retroviral Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.1.5. Plasmid DNA
21.6.1.5.1. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.1.5.2. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.1.5.3. Plasmid DNA Vector Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.6.2. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2022-2035: Distribution by Therapeutic Area
21.6.3. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2022-2035: Distribution by Application Area
21.6.4. Viral Vector and Plasmid DNA Manufacturing Market for Commercial Products, 2022-2035: Distribution by Key Geographical Regions
21.7. Current and Future Market Opportunity for Clinical Candidates
21.7.1. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Type of Vector Manufactured
21.7.2.1. AAV Vectors
21.7.2.1.1. AAV Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.1.2. AAV Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.1.3. AAV Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.2.2. Adenoviral Vectors
21.7.2.2.1. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.2.2. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.2.3. Adenoviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.2.3. Lentiviral Vectors
21.7.2.3.1. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.3.2. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.3.3. Lentiviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.2.4. Retroviral Vectors
21.7.2.4.1. Retroviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.4.2. Retroviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.4.3. Retroviral Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.2.5. Plasmid DNA
21.7.2.5.1. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Phase of Development
21.7.2.5.2. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.2.5.3. Plasmid DNA Vector Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.7.3. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Application Area
21.7.4. Viral Vector and Plasmid DNA Manufacturing Market for Clinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8. Current and Future Market Opportunity from Preclinical Candidates
21.8.1. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Vector Manufactured
21.8.1.1. AAV Vectors
21.8.1.1.1. AAV Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.1.2. AAV Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.1.3. AAV Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.1.2. Adenoviral Vectors
21.8.1.2.1. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.2.2. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.2.3. Adenoviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.1.3. Lentiviral Vectors
21.8.1.3.1. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.3.2. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.3.3. Lentiviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.1.4. Retroviral Vectors
21.8.1.4.1. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.4.2. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.4.3. Retroviral Vector Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.1.5. Plasmid DNA
21.8.1.5.1. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.1.5.2. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.1.5.3. Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.8.2. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Type of Animal Model Used
21.8.3. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Therapeutic Area
21.8.4. Viral Vector and Plasmid DNA Manufacturing Market for Preclinical Candidates, 2022-2035: Distribution by Application Area
21.8.5. Viral Vector and Plasmid DNA Manufacturing Market for preclinical Candidates, 2022-2035: Distribution by Key Geographical Regions
21.9 Current and Future Market opportunity from Vector-Based Vaccines
21.9.1. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2022-2035: Distribution by Scale of Operation
21.9.2. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2022-2035: Distribution by Type of Vector Manufactured
21.9.3. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2022-2035: Distribution by Therapeutic Area
21.9.4. Viral Vector and Plasmid DNA Manufacturing Market for Vector Based Vaccines, 2022-2035: Distribution by Key Geographical Regions

22. PORTER’S FIVE FORCES ANALYSIS

22.1 Chapter Overview
22.2. Methodology and Assumptions
22.2.1. Key Parameters
22.2.2. Threats of New Entrants
22.2.3. Bargaining Power of Suppliers
22.2.4. Threats of Substitute Products
22.2.5. Rivalry Among Existing Competitors
22.3. Concluding Remarks

23. KEY DRIVERS AND CHALLENGES

23.1. Chapter Overview
23.2. Viral Vector and Plasmid DNA Manufacturing Market: Key Drivers and Challenges
23.2.1. AAV Vectors
23.2.2. Adenoviral Vectors
23.2.3. Lentiviral Vectors
23.2.4. Retroviral Vectors
23.2.5. Plasmid DNA
23.3. Concluding Remarks

24. SURVEY ANALYSIS

24.1. Chapter Overview
24.2. Analysis by Seniority Level of Respondents
24.3. Analysis by Type of Manufacturer
24.4. Analysis by Scale of Operation
24.5. Analysis by Type of Vector Manufactured

25. CONCLUDING REMARKS

26. EXECUTIVE INSIGHTS

26.1. Chapter Overview
26.2. Batavia Biosciences
26.2.1. Company Snapshot
26.2.2. Interview Transcript: Menzo Havenga, Chief Executive Officer and President
26.3. CEVEC Pharmaceuticals
26.3.1. Company Snapshot
26.3.2. Interview Transcript: Nicole Faust, Chief Executive Officer & Chief Scientific Officer
26.4. Vigene Biosciences
26.4.1. Company Snapshot
26.4.2. Interview Transcript: Jeffrey Hung, Former Chief Commercial Officer
26.5. Delphi Genetics
26.5.1. Company Snapshot
26.5.2. Interview Transcript: Cedric Szpirer, Former Executive and Scientific Director
26.6. Clean Cells
26.6.1. Company Snapshot
26.6.2. Interview Transcript: Olivier Boisteau, Strategy Direction and Executive Board Member, Laurent Ciavatti, Former Business Development Manager and Xavier Leclerc, Head of Gene Therapy
26.7. Novasep
26.7.1. Company Snapshot
26.7.2. Interview Transcript: Alain Lamproye, Former President of Biopharma Business Unit
26.8. Amsterdam BioTherapeutics Unit (AmBTU)
26.8.1. Organization Snapshot
26.8.2. Interview Transcript: Joost van den Berg, Former Director
26.9. MGH Viral Vector Development Facility, Massachusetts General Hospital
26.9.1. Organization Snapshot
26.9.2. Interview Transcript: Bakhos Tannous, Director
26.10. Translational Vector Core, University of Nantes
26.10.1. Organization Snapshot
26.10.2. Interview Transcript: Eduard Ayuso, DVM, PhD, Scientific Director
26.11. CJ PARTNERS
26.11.1. Company Snapshot
26.11.2. Interview Transcript: Colin Lee Novick, Managing Director
26.12. ACGT
26.12.1. Company Snapshot
26.12.2. Interview Transcript: Semyon Rubinchik, Scientific Director
26.13. Richter-Helm
26.13.1. Company Snapshot
26.13.2. Interview Transcript: Astrid Brammer, Senior Manager Business Development
26.14. Plasmid Factory
26.14.1. Company Snapshot
26.14.2. Interview Transcript: Marco Schmeer, Project Manager and Tatjana Buchholz, Former Marketing Manager
26.15. Waisman Biomanufacturing
26.15.1. Company Snapshot
26.15.2. Interview Transcript: Brian M Dattilo, Business Development Manager
26.16. EFS-West Biotherapy
26.16.1. Company Snapshot
26.16.2. Interview Transcript: Beatrice Araud, ATMP Key Account Manager
26.17. GEG Tech
26.17.1. Company Snapshot
26.17.2. Interview Transcript: Nicolas Grandchamp, R&D Leader
26.18. Polypus Transfection
26.18.1. Company Snapshot
26.18.2. Interview Transcript: Géraldine Guérin-Peyrou, Director of Marketing and Technical Support
26.19. Vive Biotech
26.19.1. Company Snapshot
26.19.2. Interview Transcript: Naiara Tejados, Head of Marketing and Technology Development
26.20. Independent Consultant
26.20.1. Interview Transcript: Jeffery Hung

27. APPENDIX I: TABULATED DATA28. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Viral and Non-Viral Techniques for Gene Transfer
Figure 3.2 Vector Production: Types of Manufacturers
Figure 3.3 Viral Vectors: Manufacturing Process
Figure 4.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Figure 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Figure 4.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 4.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise )
Figure 4.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Country-wise)
Figure 4.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer and Company Size
Figure 4.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 4.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Figure 4.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 5.1 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Figure 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Figure 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Figure 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Figure 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Figure 5.6 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Figure 5.7 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Figure 5.8 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Figure 5.9 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Figure 5.10 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Figure 6.1 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Figure 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Figure 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Figure 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer and Location of Vector Manufacturing Facilities
Figure 6.5 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Figure 6.6 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 6.7 Logo Landscape: Distribution by Scale of Operation and Type of Vector Manufactured
Figure 6.8 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 7.1 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Figure 7.2 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Figure 7.3 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Figure 7.4 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Figure 7.5 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Figure 7.6 Most Active Players: Distribution by Number of Technology
Figure 8.1 Company Competitiveness Analysis: Distribution of Players based in North America (In-House Manufacturers)
Figure 8.2 Company Competitiveness Analysis: Distribution of Players based in Europe (In-House Manufacturers)
Figure 8.3 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (In-House Manufacturers)
Figure 8.4 Company Competitiveness Analysis: Distribution of Players based in North America (Contract Manufacturing Organizations)
Figure 8.5 Company Competitiveness Analysis: Distribution of Players based in Europe (Contract Manufacturing Organizations)
Figure 8.6 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Contract Manufacturing Organizations)
Figure 8.7 Company Competitiveness Analysis: Distribution of Players based in North America (Both In-House and Contract Manufacturing Organizations)
Figure 8.8 Company Competitiveness Analysis: Distribution of Players based in Europe (Both In-House and Contract Manufacturing Organizations)
Figure 8.9 Company Competitiveness Analysis: Distribution of Players based in Asia-Pacific and Rest of the World (Both In-House and Contract Manufacturing Organizations)
Figure 9.1 Danaher: Annual Revenues, 2014 - Q1 2022 (USD Billion)
Figure 9.2 Merck KGaA: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Figure 9.3 H.A.V.E.: AAV Vector Manufacturing Technology
Figure 9.4 bluebird bio: Annual Revenues, 2014 - Q1 2022 (USD Million)
Figure 9.5 Astellas Pharma: Annual Revenues, 2014 - 2021 (JPY Billion)
Figure 9.6 Emergent BioSolutions: Annual Revenues, 2014 - 2021 (USD Million)
Figure 9.7 FUJIFILM Holdings: Annual Revenues, 2013 - H1 FY 2021 (JPY Billion)
Figure 9.8 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Figure 9.8 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Figure 10.1 Charles River Laboratories: Annual Revenues, 2017 - Q1 2022 (USD Billion)
Figure 10.2 Lonza: Annual Revenues, 2014 - 2021 (CHF Billion)
Figure 10.3 AGC Biologics: Annual Revenues, 2020 - 2022 (JPY Billion)
Figure 10.4 Novasep: Viral Vector Manufacturing Process
Figure 10.5 Oxford BioMedica: Annual Revenues, 2014 - 2021 (GBP Million)
Figure 10.6 Sanofi: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Figure 10.7 uniQure: Annual Revenues, 2014 - Q1 2022 (USD Million)
Figure 11.1 Wuxi AppTec: Annual Revenues, 2017 - H1 2022 (RMB Million)
Figure 12.1 Thermo Fisher Scientific: Annual Revenues, 2017-Q1 2022 (USD Billion)
Figure 12.2 BioNTech Innovative Manufacturing: Annual Revenues, 2017-Q1 2022 (EUR Billion)
Figure 13.1 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2022
Figure 13.2 Recent Partnerships: Distribution by Type of Partnership
Figure 13.3 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2022
Figure 13.4 Recent Partnerships: Distribution by Scale of Operation
Figure 13.5 Recent Partnerships: Distribution by Type of Vector(s)
Figure 13.6 Recent Partnerships: Distribution by Therapeutic Area
Figure 13.7 Most Active Players: Distribution by Number of Partnerships
Figure 13.8 Recent Partnerships: Geographical Analysis
Figure 13.9 Recent Partnerships: Intercontinental and Intracontinental Agreements
Figure 14.1 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2022
Figure 14.2 Recent Expansions: Distribution by Type of Expansion, 2015 - 2022
Figure 14.3 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2022
Figure 14.4 Recent Expansions: Distribution of Amount Invested by Key Players
Figure 14.5 Recent Expansions: Distribution by Scale of Operation
Figure 14.6 Recent Expansions: Distribution by Type of Vector(s)
Figure 14.7 Recent Expansions: Distribution by Application Area
Figure 14.8 Most Active Players: Distribution by Number of Expansions
Figure 14.9 Recent Expansions: Intercontinental and Intracontinental Expansions
Figure 14.10 Recent Expansions: Distribution by Location of Expansion Project
Figure 17.1 Vector and Gene Therapy Manufacturers: Competitive Landscape by Type of Manufacturer, Type of Vector Manufactured and Scale of Operation
Figure 17.2 Vector and Gene Therapy Manufacturers: Logo Landscape by Company Size and Type of Vector Manufactured
Figure 17.3 Vector and Gene Therapy Contract Manufacturers: Distribution by Prominent Geographical Hubs
Figure 17.4 Vector and Gene Therapy In-House Manufacturers: Distribution by Prominent Geographical Hubs
Figure 17.5 AAV Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.6 Adenoviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.7 Lentiviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.8 Retroviral Vector Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 17.9 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 18.1 Viral Vector and Plasmid DNA Cost Price Analysis: Vector Production Process and Relative Costs Involved
Figure 19.1 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Figure 19.2 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Figure 19.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 19.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 19.5 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 19.6 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 19.7 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of operation (in Liters)
Figure 19.8 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Figure 19.9 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Figure 19.10 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 19.11 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale of operation
Figure 19.12 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Figure 20.1 Global Clinical Demand for Viral Vector and Plasmid DNA, 2022-2035 (Thousand Patients)
Figure 20.2 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 20.3 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 20.4 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 20.5 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 20.6 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Figure 20.7 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Figure 20.8 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Figure 20.9 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Figure 20.10 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Figure 20.11 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2022-2035
Figure 20.12 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2022-2035
Figure 20.13 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2022-2035
Figure 21.1 Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035 (USD Million)
Figure 21.2 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.3 Viral Vector and Plasmid DNA Manufacturing Market: Market Attractiveness Analysis by Type of Vector Manufactured, 2022-2035
Figure 20.4 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.5 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Figure 20.6 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 20.7 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Manufacturer, 2022-2035 (USD Million)
Figure 20.8 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.9 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.10 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Figure 20.11 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Figure 20.12 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2022, 2028 and 2035 (USD Million)
Figure 20.13 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.14 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 20.15 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.16 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.17 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 20.18 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 20.19 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 20.20 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.21 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.22 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.23 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.24 Retroviral Vector Manufacturing Market for Commercial Product: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.25 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.26 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.27 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.28 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.29 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.30 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Figure 21.31 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.32 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.33 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.34 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.35 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.36 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.37 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.38 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.39 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.40 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.41 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.42 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.43 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.44 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.45 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Figure 21.46 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.47 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.48 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2022, 2025 and 2035 (USD Million)
Figure 21.49 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Animal Model Used, 2022-2035 (USD Million)
Figure 21.50 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022, 2025 and 2035 (USD Million)
Figure 21.51 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.52 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.53 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.54 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.55 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.56 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.57 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.58 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.59 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.60 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.61 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.62 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.63 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.64 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Figure 21.65 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Figure 21.66 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 21.67 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Figure 21.68 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 21.69 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 21.70 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Figure 22.1 Porter’s Five Forces
Figure 22.2 Porter’s Five Forces: Harvey Ball Analysis
Figure 23.1 Key Drivers and Challenges: AAV Vectors
Figure 23.2 Key Drivers and Challenges: Adenoviral Vectors
Figure 23.3 Key Drivers and Challenges: Lentiviral Vectors
Figure 23.4 Key Drivers and Challenges: Retroviral Vectors
Figure 23.5 Key Drivers and Challenges: Plasmid DNA
Figure 24.1 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 24.2 Survey Analysis: Distribution by Scale of operation
Figure 24.3 Survey Analysis: Distribution by Type of Vector Manufactured
Figure 25.1 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Viral Vectors
Figure 25.2 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Plasmid DNA
Figure 25.3 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Non-Industry Players
Figure 25.4 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Current Market Landscape of Vector and Gene Therapy manufacturing Technologies
Figure 25.5 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Recent Expansions and Partnerships
Figure 25.6 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Strategic Partner Analysis
Figure 25.7 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Capacity Analysis
Figure 25.8 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Demand Analysis
Figure 25.9 Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing DNA Market: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Key Features of Viral Vectors
Table 3.2 Key Features of Small-scale Cell Culture Systems
Table 4.1 Viral Vector and Gene Therapy Manufacturers: List of Industry Players
Table 4.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Location of Viral Vector Manufacturing Facilities, Scale of operation and Type of Manufacturer
Table 4.3 Heat Map: Information on Location of Headquarters and Scale of operation
Table 4.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Vector Manufactured
Table 4.5 Heat Map: Information on Scale of operation and Type of Viral Vector Manufactured
Table 4.6. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 4.7. Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 5.1 Plasmid DNA and Gene Therapy Manufacturers: List of Industry Players
Table 5.2 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Company Size and Location of Headquarters
Table 5.3 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Location of Plasmid DNA Manufacturing Facilities, Scale of operation and Type of Manufacturer
Table 5.4 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Application Area
Table 5.5 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Information on Production Capacity
Table 6.1 Vector and Gene Therapy Manufacturers: List of Non-Industry Players
Table 6.2 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Scale of operation
Table 6.3 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Type of Vector Manufactured
Table 6.4 Vector and Gene Therapy Manufacturers (Non-Industry Players): Information on Application Area
Table 7.1 Vector and Gene Therapy Manufacturing Technologies: List of Technology Platforms
Table 9.1 Vector and Gene Therapy Production in North America: List of Profiled Companies
Table 9.2 Advanced BioScience Laboratories: Recent Developments and Future Outlook
Table 9.3 Aldevron Plasmid DNA: QC Assays
Table 9.4 Aldevron: Recent Developments and Future Outlook
Table 9.5 Audentes Therapeutics: Recent Developments and Future Outlook
Table 9.6 BioReliance / SAFC Commercial (Merck KGaA): Recent Developments and Future Outlook
Table 9.7 bluebird bio: Recent Developments and Future Outlook
Table 9.8 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 9.10 MeiraGTx: Recent Developments and Future Outlook
Table 9.11 MassBiologics: Recent Developments and Future Outlook
Table 9.12 Spark Therapeutics: Recent Developments and Future Outlook
Table 9.13 Vigene Biosciences: Recent Developments and Future Outlook
Table 10.1 Vector and Gene Therapy Production in Europe: List of Players Profiled
Table 10.2 Biovian: Recent Developments and Future Outlook
Table 10.3 Centre for Process Innovation: Recent Developments and Future Outlook
Table 10.4 Cobra Biologics: Recent Developments and Future Outlook
Table 10.5 FinVector: Recent Developments and Future Outlook
Table 10.6 Kaneka Eurogentec: Recent Developments and Future Outlook
Table 10.7 Lonza: Recent Developments and Future Outlook
Table 10.8 MolMed: Recent Developments and Future Outlook
Table 10.9 Novasep: Manufacturing Experience
Table 10.10 Novasep: Recent Developments Future Outlook
Table 10.11 Orchard Therapeutics: Recent Developments Future Outlook
Table 10.12 Oxford BioMedica: Recent Developments and Future Outlook
Table 10.13 Richter-Helm: Recent Developments and Future Outlook
Table 10.14 Sanofi: Recent Developments and Future Outlook
Table 10.15 uniQure: Recent Developments and Future Outlook
Table 10.16 Vibalogics: Recent Developments and Future Outlook
Table 10.17 VIVEbiotech: Recent Developments and Future Outlook
Table 10.18 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 11.1 Wuxi AppTec: Recent Developments and Future Outlook
Table 11.2 List of Other Key Players Based in Asia Pacific
Table 13.1 Vector and Gene Therapy Manufacturing: List of Recent Partnerships, 2015-2020 (till September)
Table 13.2 Vector and Gene Therapy Manufacturing: List of Other Partnerships, 2015-2020 (till September)
Table 13.1 Vector and Gene Therapy Manufacturing: List of Recent Expansions, 2015-2020 (till September)
Table 13.2 Vector and Gene Therapy Manufacturing: Information on Scale of operation, Type of Vector Manufactured and Application Area, 2015-2020 (till September)
Table 13.1 AAV Vector-based Therapy Developers: Most Likely Partners
Table 15.2 AAV Vector-based Therapy Developers: Likely Partners
Table 15.3 AAV Vector-based Therapy Developers: Less Likely Partners
Table 15.4 AAV Vector-based Therapy Developers: Least Likely Partners
Table 15.5 Adenoviral Vector-based Therapy Developers: Most Likely Partners
Table 15.6 Adenoviral Vector-based Therapy Developers: Likely Partners
Table 15.7 Adenoviral Vector-based Therapy Developers: Less Likely Partners
Table 15.8 Adenoviral Vector-based Therapy Developers: Least Likely Partners
Table 15.9 Lentiviral Vector-based Therapy Developers: Most Likely Partners
Table 15.10 Lentiviral Vector-based Therapy Developers: Likely Partners
Table 15.11 Lentiviral Vector-based Therapy Developers: Less Likely Partners
Table 15.12 Lentiviral Vector-based Therapy Developers: Least Likely Partners
Table 15.13 Retroviral Vector-based Therapy Developers: Most Likely Partners
Table 15.14 Retroviral Vector-based Therapy Developers: Likely Partners
Table 15.15 Retroviral Vector-based Therapy Developers: Less Likely Partners
Table 15.16 Retroviral Vector-based Therapy Developers: Least Likely Partners
Table 15.17 Other Viral Vector-based Therapy Developers: Most Likely Partners
Table 15.18 Other Viral Vector-based Therapy Developers: Likely Partners
Table 15.19 Other Viral Vector-based Therapy Developers: Less Likely Partners
Table 15.20 Other Viral Vector-based Therapy Developers: Least Likely Partners
Table 15.21 AAV Vector Purification Product Developers: Most Likely Partners
Table 15.22 AAV Vector Purification Product Developers: Likely Partners
Table 15.23 Adenoviral Vector Purification Product Developers: Most Likely Partners
Table 15.24 Adenoviral Vector Purification Product Developers: Likely Partners
Table 15.25 Lentiviral Vector Purification Product Developers: Most Likely Partners
Table 15.26 Lentiviral Vector Purification Product Developers: Likely Partners
Table 15.27 Retroviral Vector Purification Product Developers: Most Likely Partners
Table 15.28 Retroviral Vector Purification Product Developers: Likely Partners
Table 15.29 Other Viral Vector Purification Product Developers: Most Likely Partners
Table 15.30 Other Viral Vector Purification Product Developers: Likely Partners
Table 18.1 Viral Vector and Plasmid DNA Cost Price Analysis: Expert Opinions / Primary Research
Table 18.2 Viral Vector and Plasmid DNA: Prices of Vectors
Table 19.1 Global Installed Viral Vector Manufacturing Capacity: Sample Data Set
Table 19.2 Global Installed Plasmid DNA Manufacturing Capacity: Sample Data Set
Table 19.3 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size
Table 19.4 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size
Table 20.1. Global Viral Vectors Manufacturing Annual Demand, 2022-2035 (1020 vg)
Table 20.2 Global Viral Vectors Manufacturing Annual Supply (Scenario 1), 2022-2035 (1020 vg)
Table 20.3 Global Viral Vector Manufacturing: Annual Supply (Scenario 2), 2022-2035 (1020 vg)
Table 20.4 Global Viral Vector Manufacturing: Annual Supply (Scenario 3), 2022-2035 (1020 vg)
Table 21.1 Viral Vector and Plasmid DNA: Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 21.2 Viral Vector and Plasmid DNA: Distribution by Patients Enrolled in the Active Clinical Studies (Vector-Based Cell and Gene Therapies)
Table 21.3 Viral Vector and Plasmid DNA: Number of Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2022-2035
Table 21.4 Viral Vector and Plasmid DNA: Number of Patients Enrolled in Active Clinical Trials (Vector-Based Cell and Gene Therapies), 2022-2035
Table 21.5 Viral Vector and Plasmid DNA: Approved / Late-Stage Cell and Gene Therapies
Table 24.1 Survey Response: Overview of the Participating Companies / Organizations
Table 24.2 Survey Response: Seniority Level of Respondents
Table 24.3 Survey Response: Type of Vector
Table 24.4 Survey Response: Scale of operation
Table 24.5 Survey Response: Vector Stabilization Technology
Table 24.6 Survey Response: Type of Manufacturer (In-house Production versus Contract Services)
Table 26.1 Batavia Biosciences: Key Highlights
Table 26.2 CEVEC Pharmaceuticals: Key Highlights
Table 26.3 Vigene Biosciences: Key Highlights
Table 26.4 Delphi Genetics: Key Highlights
Table 26.5 Clean Cells: Key Highlights
Table 26.6 Novasep: Key Highlights
Table 26.7 Amsterdam BioTherapeutics Unit (AmBTU): Key Highlights
Table 26.8 MGH Viral Vector Development Facility, Massachusetts General Hospital: Key Highlights
Table 26.9 Translational Vector Core, University of Nantes: Key Highlights
Table 26.10 CJ PARTNERS: Key Highlights
Table 26.11 ACGT: Key Highlights
Table 26.12 Richter-Helm: Key Highlights
Table 26.13 Plasmid Factory: Key Highlights
Table 26.14 Waisman Biomanufacturing: Key Highlights
Table 26.15 EFS-West Biotherapy: Key Highlights
Table 26.16 GEG Tech: Key Highlights
Table 27.1 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 27.2 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 27.3 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Table 27.4 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Table 27.5 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 27.6 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise )
Table 27.7 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Country-wise)
Table 27.8 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer and Company Size
Table 27.9 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 27.10 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Vector Manufactured
Table 27.11 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 27.12 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Year of Establishment
Table 27.13 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Company Size
Table 27.14 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Continents)
Table 27.15 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters (Countries)
Table 27.16 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Product Manufactured
Table 27.17 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Continents)
Table 27.18 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Plasmid DNA Manufacturing Facilities (Countries)
Table 27.19 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Manufacturer
Table 27.20 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
Table 27.21 Plasmid DNA and Gene Therapy Manufacturers (Industry Players): Distribution by Application Area
Table 27.22 Vector and Gene Therapy Manufacturers (Non-Industry Players): Cumulative Trend by Year of Establishment
Table 27.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Continents)
Table 27.24 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Location of Vector Manufacturing Facilities (Countries)
Table 27.25 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Manufacturer and Location of Vector Manufacturing Facilities
Table 27.26 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
Table 27.27 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 27.28 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Application Area
Table 27.29 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Technology
Table 27.30 Vector and Gene Therapy Manufacturing Technologies: Distribution by Purpose of Technology
Table 27.31 Vector and Gene Therapy Manufacturing Technologies: Distribution by Scale of Operation
Table 27.32 Vector and Gene Therapy Manufacturing Technologies: Distribution by Type of Vector Manufactured
Table 27.33 Vector and Gene Therapy Manufacturing Technologies: Distribution by Application Area
Table 27.34 Most Active Players: Distribution by Number of Technology
Table 27.35 Danaher: Annual Revenues, 2014 - Q1 2022 (USD Billion)
Table 27.36 Merck KGaA: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Table 27.37 bluebird bio: Annual Revenues, 2014 - Q1 2022 (USD Million)
Table 27.38 Astellas Pharma: Annual Revenues, 2014 - 2021 (JPY Billion)
Table 27.39 Emergent BioSolutions: Annual Revenues, 2014 - 2021 (USD Million)
Table 27.40 FUJIFILM Holdings: Annual Revenues, 2013 - H1 FY 2021 (JPY Billion)
Table 27.41 FUJIFILM Holdings: Revenues by Business Divisions, FY 2020 (JPY Billion)
Table 27.42 Spark Therapeutics: Annual Revenues, 2014 - 9M 2019 (USD Million)
Table 27.43 Charles River Laboratories: Annual Revenues, 2017 - Q1 2022 (USD Billion)
Table 27.44 Lonza: Annual Revenues, 2014 - 2021 (CHF Billion)
Table 27.45 AGC Biologics: Annual Revenues, 2020 - 2022 (JPY Billion)
Table 27.46 Oxford BioMedica: Annual Revenues, 2014 - 2021 (GBP Million)
Table 27.47 Sanofi: Annual Revenues, 2014 - Q1 2022 (EUR Billion)
Table 27.48 uniQure: Annual Revenues, 2014 - Q1 2022 (USD Million)
Table 27.49 Wuxi AppTec: Annual Revenues, 2017 - H1 2022 (RMB Million)
Table 27.50 Thermo Fisher Scientific: Annual Revenues, 2017-Q1 2022 (USD Billion)
Table 27.51 BioNTech Innovative Manufacturing: Annual Revenues, 2017-Q1 2022 (EUR Billion)
Table 27.52 Recent Partnerships: Cumulative Year-wise Trend, 2015 - 2022
Table 27.53 Recent Partnerships: Distribution by Type of Partnership
Table 27.54 Recent Partnerships: Distribution by Type and Year of Partnership, 2015 - 2022
Table 27.55 Recent Partnerships: Distribution by Scale of Operation
Table 27.56 Recent Partnerships: Distribution by Type of Vector(s)
Table 27.57 Recent Partnerships: Distribution by Therapeutic Area
Table 27.58 Most Active Players: Distribution by Number of Partnerships
Table 27.59 Recent Partnerships: Geographical Analysis
Table 27.60 Recent Partnerships: Intercontinental and Intracontinental Agreements
Table 27.61 Recent Expansions: Cumulative Year-wise Trend, 2015 - 2022
Table 27.62 Recent Expansions: Distribution by Type of Expansion, 2015 - 2022
Table 27.63 Recent Expansions: Distribution by Type and Year of Expansion, 2015 - 2022
Table 27.64 Recent Expansions: Distribution of Amount Invested by Key Players
Table 27.65 Recent Expansions: Distribution by Scale of Operation
Table 27.66 Recent Expansions: Distribution by Type of Vector(s)
Table 27.67 Recent Expansions: Distribution by Application Area
Table 27.68 Most Active Players: Distribution by Number of Expansions
Table 27.69 Recent Expansions: Intercontinental and Intracontinental Expansions
Table 27.70 Recent Expansions: Distribution by Location of Expansion Project
Table 27.71 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Type of Vector Manufactured (in Liters)
Table 27.72 Global Installed Viral Vector and Plasmid DNA Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (in Liters)
Table 27.73 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 27.74 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Table 27.75 Global Installed Viral Vector Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 27.76 Global Installed Viral Vector Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 27.77 Global Installed Viral Vector Manufacturing Capacity: Distribution by Scale of Operation (in Liters)
Table 27.78 Global Installed Viral Vector Manufacturing Capacity: Distribution by Geographical Location of Viral Vector Manufacturing Facilities (in Liters)
Table 27.79 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Company Size (in Liters)
Table 27.80 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 27.81 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Scale ofOperation
Table 27.82 Global Installed Plasmid DNA Manufacturing Capacity: Distribution by Location of Plasmid DNA Manufacturing Facilities (in Liters)
Table 27.83 Global Clinical Demand for Viral Vector and Plasmid DNA, 2022-2035 (Thousand Patients)
Table 27.84 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Table 27.85 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 27.86 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 27.87 Clinical Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 27.88 Global Commercial Demand for Viral Vector and Plasmid DNA (Thousand Patients)
Table 27.89 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Vector Manufactured (Thousand Patients)
Table 27.90 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Type of Therapy (Thousand Patients)
Table 27.91 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Therapeutic Area (Thousand Patients)
Table 27.92 Commercial Demand for Viral Vector and Plasmid DNA: Distribution by Geographical Location (Thousand Patients)
Table 27.93 Global Viral Vector Manufacturing: Demand and Supply (Scenario 1), 2022-2035
Table 27.94 Global Viral Vector Manufacturing: Demand and Supply (Scenario 2), 2022-2035
Table 27.95 Global Viral Vector Manufacturing: Demand and Supply (Scenario 3), 2022-2035
Table 27.96 Viral Vector and Plasmid DNA Manufacturing Market, 2022-2035 (USD Million)
Table 27.97 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.98 Viral Vector and Plasmid DNA Manufacturing Market: Market Attractiveness Analysis by Type of Vector Manufactured, 2022-2035
Table 27.99 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.100 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Table 27.101 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 27.102 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Type of Manufacturer, 2022-2035 (USD Million)
Table 27.103 Viral Vector and Plasmid DNA Manufacturing Market: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.104 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.105 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022, 2028 and 2035 (USD Million)
Table 27.106 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Table 27.107 Viral Vectors and Plasmid DNA Manufacturing Market for Commercial Products: Distribution by Type of Vector Manufactured, 2022, 2028 and 2035 (USD Million)
Table 27.108 AAV Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.109 AAV Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.110 AAV Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.111 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.112 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.113 Adenoviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.114 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.115 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.116 Lentiviral Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.118 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.119 Retroviral Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.120 Retroviral Vector Manufacturing Market for Commercial Product: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.121 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.122 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.123 Plasmid DNA Vector Manufacturing Market for Commercial Products: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.124 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.125 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.126 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022, 2028 and 2035 (USD Million)
Table 27.127 Viral Vectors and Plasmid DNA Manufacturing Market for Clinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.128 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.129 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.130 AAV Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.131 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.132 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.133 Adenoviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.134 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.135 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.136 Lentiviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.137 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.138 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.139 Retroviral Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.140 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.141 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Phase of Development, 2022-2035 (USD Million)
Table 27.142 Plasmid DNA Vector Manufacturing Market for Clinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.143 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.144 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Therapeutic Area, 2022, 2025 and 2035 (USD Million)
Table 27.145 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.146 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022, 2025 and 2035 (USD Million)
Table 27.147 Viral Vectors and Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.148 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.149 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.150 AAV Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.151 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.152 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.153 Adenoviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.154 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.155 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.156 Lentiviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.157 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.158 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.159 Retroviral Vector Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.160 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Application Area, 2022-2035 (USD Million)
Table 27.161 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Type of Animal Model Used, 2022-2035 (USD Million)
Table 27.162 Plasmid DNA Manufacturing Market for Preclinical Candidates: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.163 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Type of Vector Manufactured, 2022-2035 (USD Million)
Table 27.164 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 27.165 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 27.166 Viral Vectors and Plasmid DNA Manufacturing Market for Vector Based Vaccines: Distribution by Key Geographical Regions, 2022-2035 (USD Million)
Table 27.167 Survey Analysis: Distribution by Seniority Level of Respondents
Table 27.168 Survey Analysis: Distribution by Scale of operation
Table 27.169 Survey Analysis: Distribution by Type of Vector Manufactured

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

4D Molecular Therapeutics
AavantiBio
Abbott
AbbVie
Abeona Therapeutics
Abintus Bio
Accinov (acquired by Advanced BioScience Laboratories)
Acucela
Adaptimmune Therapeutics
AdaptVac
Addgene
Aduro Biotech
Advaccine
Advanced BioScience Laboratories
Advanced Biotherapeutics Consulting
Advantagene
Advaxis
Advent
Adverum Biotechnologies (formerly Avalanche Biotechnologies)
Aevitas Therapeutics (subsidiary of Fortress Biotech)
AffyImmune Therapeutics
AffyXel
AGC Biologics
Agilent Technologies
Agilis Biotherapeutics (acquired by PTC Therapeutics)
AGTC
Ajinomoto Bio-Pharma Services
Akdeniz University
Akron Biotech
Albumedix
Aldevron
Allele Biotechnology
Allergan
Allife Medicine
Allogene Therapeutics
Alma Bio Therapeutics
AlphaVax
ALSTEM
Althea Technologies
Altimmune
Altor BioScience
American Gene Technologies
Amgen
Amicus Therapeutics
Ampersand Capital Partners
AMSBIO
Amsterdam BioTherapeutics Unit
Amsterdam Molecular Therapeutics (acquired by uniQure)
Anaeropharma Science
Andelyn Biosciences
Anemocyte
AnGes
Angionetics
ANLBIO
Annapurna Therapeutics (acquired by Avalanche Biotechnologies)
apceth Biopharma
Applied Biological Materials
Applied Genetic Technologies (AGTC)
Applied Viromics
Arcellx
ArcticZymes Technologies
Areta International
Aruvant Sciences
ASC Therapeutics
AskBio
Asklepios BioPharmaceutical
Astellas Pharma
AstraZeneca
Atara Biotherapeutics
Atlantic Bio GMP (subsidiary of Atlanpole Biotherapies)
Atsena Therapeutics
Audentes Therapeutics (acquired by Astella Pharma)
Aurora Biopharma
Autolus Therapeutics
Avantor
Avecia Biologics
Avid Bioservices
AVROBIO
Axovant Gene Therapies
Bamboo Therapeutics
Batavia Biosciences
Baylor College of Medicine
BCM Families Foundation
Biological E.
Beam Therapeutics
Beckman Research Institute
Beijing Biohealthcare Biotechnology
Beijing Doing Biomedical
Beijing HuiNengAn Biotech
Beijing Immunochina Medical Science & Technology
Beijing Mario Biotech
Beijing Sanwater Biological Technology
Bellicum Pharmaceuticals
Benitec Biopharma
BIA Separations (Acquired by Sartorius)
Bioceltech Therapeutics
97. BioCentriq (Acquired by GC)
Biogen
Bio-Gene Technology
BioInvent International
BioMarin Pharmaceuticals
Biomay
Biomiga
Bionic Sight
BioNTech Innovative Manufacturing Service (formerly known as Eufects)
Bio-Rad Laboratories
BioReliance
BioVec Pharma
Bioverativ
Biovian
BioVision
Blue Sky BioServices (subsidiary of LakePharma)
bluebird bio (formerly known as Genetix Pharmaceuticals)
BMS
Boehringer Ingelheim BioXcellence
BoYuan RunSheng Pharma
Brain Neurotherapy Bio
Brammer Bio (acquired by Thermo Fisher Scientific)
Brazilian Biosciences National Laboratory (LNBio)
Bristol Myers Squibb
Cabaletta Bio
Caltech
Cambridge Gene Therapy
Candel Therapeutics
Capsugel
Carina Biotech
Carmine Therapeutics
CARsgen Therapeutics
Cartesian Therapeutics
Casey Eye Institute
Castle Creek Biosciences
Catalent Biologics
Celgene
Cell and Gene Therapy Catapult
Cell Biolabs
Cellectis
CellGenTech
Cellular Biomedicine Group
Cellvec
Celonic
Celsion
Celyad Oncology
Center for Breakthrough Medicines
Centre for Commercialization of Regenerative Medicine
Centre for Process Innovation
CEVEC Pharmaceuticals
CG Oncology
Children’s Medical Research Institute (CMRI)
Children's Hospital of Philadelphia
China Immunotech Biotechnology
Choroideremia Research Foundation
Cincinnati Children's Hospital Medical Center
City of Hope
Clean Cells
Clino
Cobra Biologics (acquired by Charles River Laboratories)
Cognate BioServices (acquired by Charles River Laboratories)
CombiGene
Copernicus Therapeutics
Cornell University
Creative Biogene
Creative Biolabs
CSL Behring
Cytiva (formerly known as GE Healthcare Life Sciences)
CytoMed Therapeutics
Cytovance Biologics
Daiichi Sankyo
Decibel
Delphi Genetics
Denali Therapeutics
DINAQOR
DNAtrix
Duke University
Durham
Dyno Therapeutics
Editas Medicine
ElevateBio
Elixirgen Scientific
Emendo Biotherapeutics
Emergent Biosolutions
Emory University School of Medicine
enGene
Epeius Biotechnologies
Errant Gene Therapeutics
ERYTECH Pharma
ESCO Aster
Esteve
eTheRNA immunotherapies
EUFETS
Eureka Biotechnology
Eurofins Genomics
Eurofins Scientific
ExcellGene
Exothera
Expression Therapeutics
Eyevensys
Fate Therapeutics
FerGene
FIMA
FinVector (formerly Ark Therapeutics)
Five Prime Therapeutics
Flash Therapeutics
Flexion Therapeutics
Florida Biologix
Formula Pharmaceuticals
Fortress Biotech
Fosun Pharma
Foundation Fighting Blindness
Fraunhofer Institute for Toxicology and Experimental Medicine
Freeline Therapeutics
Fujifilm Diosynth Biotechnologies
Fundamenta Therapeutics
G-CON Manufacturing
GE Healthcare Life Sciences
GEG Tech
Genable Technologies
Genecopoeia
GeneCure Biotechnologies
GeneDetect
GeneImmune Biotechnology
Genelux
GeneMedicine
Genenta Science
GeneOne Life Science
Genethon
GENEWIZ
Genexine
Genezen Laboratories
GenIbet Biopharmaceuticals
Genopis
Genprex
GenScript
GenSight Biologics
GenVec
Gen-X
Genzyme
GeoVax Labs
GIGA
GlaxoSmithKline
Gracell Biotechnologies
Gradalis
Green Cross LabCell
Grousbeck Gene Therapy Center
Guangdong Xiangxue Precision Medical Technology
Guangdong Zhaotai InVivo Biomedicine
Guangzhou Anjie Biomedical Technology
Guangzhou FineImmune Biotechnology
Gyroscope Therapeutics
Hadassah Medical Organization
HaemaLogiX
Handl Therapeutics
Harvard Gene Therapy Initiative
Hebei Senlang Biotechnology
Heidelberg University Hospital
Helixmith
Hemera Biosciences
Henan Hualong Biotechnology
Herantis Pharma
Hitachi Chemical Advanced Therapeutics Solutions
Holostem Terapie Avanzate
Homology Medicines
Hong Kong Institute of Biotechnology
Hookipa Biotech
HORAMA
Hrain Biotechnology
Huadao biomedical
Huapont Life Sciences
Human Stem Cells Institute (HSCI)
Hunan Zhaotai Yongren Medical Innovation
Icahn School of Medicine at Mount Sinai
iCAR Bio Therapeutics
iCarTAB BioMed
iCell Gene Therapeutics
ID Pharma (formerly DNAVEC)
IDT Biologika
Ilya Pharma
Immatics
Immune Design
Immune Technology
Immunocore
Immunomic Therapeutics
Imperial Innovations
Imperial Innovations
Indiana University
Innovative Cellular Therapeutics
InnovaVector
INOVIO Pharmaceuticals
InProTher
Institute of Medical Science Research Hospital
Institute of Translational Health Sciences
International AIDS Vaccine Initiative (IAVI)
InvivoGen
IPPOX Foundation
IQVIA (formerly QuintilesIMS)
Iveric Bio
Jansen Pharmaceuticals
Juno therapeutics
Juventas Cell Therapy
JW Therapeutics
KAEDI
Kaneka Eurogentec
Karolinska University Hospital
Kavli Institute for Systems Neuroscience
Kecellitics Biotech
King's College London
Kite Pharma (subsidiary of the Gilead Sciences)
Kobe Biomedical Innovation Cluster
Kolon TissueGene
Kriya Therapeutics
Krystal Biotech
Kuur Therapeutics
Laboratory of Digital Sciences of Nantes
LakePharma
Legend Biotech
Leiden University Medical Centre
Lentigen Technology (subsidiary of Miltenyi Biotec)
Leucid Bio
Leukocare
Leuven Viral Vector Core (LVVC)
Lexeo
LEXEO Therapeutics
Lion TCR
Lipigon Pharmaceuticals
LNBio
LogicBio Therapeutics
Lokon Pharma
Lonza
Louisiana State University School of Veterinary Medicine
Luina Bio
Luminous BioSciences
Lund University
Lysogene
Magee-Womens Research Institute
Maine Medical Center Research Institute (MMCRI)
MaineHealth Institute for Research
MangoGen Pharma
Marino Biotechnology
Mass Biologics
Massachusetts Eye and Ear
Massachusetts General Hospital
MassBiologics
MaxCyte
Mayflower Bioscience
Mayo Clinic Cancer Center
McMaster Immunology Research Center (MIRC)
MD Anderson Cancer Institute
Medac
Medigene
MedImmune
MeiraGTx
Memorial Sloan Kettering Cancer Center
Merck
Microsoft
Mila’s Miracle Foundation
MilliporeSigma
Milo Biotechnology
Miltenyi Biotec
Minaris Regenrative Medicine
Minerva Biotechnologies
MingJu Therapeutics
Mitsubishi Tanabe Pharma
Moderna
Molecular Diagnostic Services
MolMed (acquired by AGC Biologics)
Momotaro-Gene
MultiVir
Mustang Bio
Myeloma Crowd
Nanjing Bioheng Biotech
Nantes Gene Therapy Institute
Naobios (subsidiary of Clean Biologics)
National Cancer Institute
National Center for Advancing Translational Sciences
National Human Genome Research Institute
National Institute of Allergy and Infectious Diseases
National Institute of Environmental Health Sciences
National Institute of Neurodegenerative Disorders and Stroke
Nationwide Children's Hospital
Nature Technology (acquired by Aldevron)
Naval Medical Research Center
Neurimmune
NeuroCure
Neurophth Therapeutics
Neuroscience Center Zurich
New Jersey Innovation Institute (NJII)
NewLink Genetics
NHS Blood and Transplant
Nikon CeLL innovation
Noga therapeutics
Norgen Biotek
Nouscom
Novartis
Novartis Gene Therapies
Novasep
Oxford Genetics
OXGENE
OZ Biosciences
PACT Pharma
Pall Biotech
Paragon Bioservices
Passage Bio
PeriphaGen
PerkinElmer
PersonGen BioTherapeutics
Peter MacCallum Cancer Centre
Pfizer
PharmaCell
Phion Therapeutics
PhorMed
Pinze Lifetechnology
PlasmidFactory
Poseida Therapeutics
Precigen
Precision BioSciences
Pregene Biotechnology
Prevail Therapeutics
Prime Vector Technologies (PVT)
ProBioGen
PROGEN
Progenics Pharmaceuticals
ProMab Biotechnologies
Protheragen
Provecs Medical
PsiOxus Therapeutics
PTC Therapeutics
Puresyn
Quethera (acquired by Astellas Pharma)
Regeneron Pharmaceuticals
RegenxBio
ReiThera
Renova Therapeutics
Rentschler Biopharma
Resilience
Richter-Helm BioLogics
Roche
Rocket Pharmaceuticals
Roswell Park Comprehensive Cancer Center
Rubius Therapeutics
Rznomics
SAB Technology
SAFC
Saiba Biotech
Salk
Sanford Burnham Prebys
Sangamo Therapeutics
Sanofi
Santen Pharmaceutical
Sarepta Therapeutics
Sartorius Stedim Biotech
Scancell
Seattle Children's Research Institute (SCRI)
Selecta Biosciences
Sensorion
Senti Biosciences
Servier
Shanghai Biomed-union Biotechnology
Shanghai Bioray Laboratory
Shanghai Cell Therapy Group
Shanghai GeneChem
Shanghai Longyao Biotechnology
Shanghai PerHum Therapeutics
Shanghai Sunway Biotech
Shanghai Unicar-Therapy Bio-medicine Technology
Shenzhen Binde Biotechnology
Shenzhen SiBiono GeneTech
SignaGen Laboratories
SillaJen
Simcere Pharmaceutical
Sinobioway Cell Therapy
SIRION Biotech
Skyline Therapeutics (formerly Geneception)
Solid Biosciences
Sorrento Therapeutics
Spark Therapeutics
SQZ Biotechnologies
St. Jude Children's Research Hospital
Stanford University
Symbiosis Pharmaceutical Services
Synpromics
Synthace
System Biosciences
Takara Bio
Takeda Pharmaceutical
Tamid Bio (subsidiary of Fortress Biotech)
Targovax
Taysha Gene Therapies
TCR2 Therapeutics
TCRCure Biopharma
tebu-bio
Telethon Institute of Genetics and Medicine (TIGM)
Terry Fox Laboratory
Tessa Therapeutics
The Beijing Pregene Science and Technology
The Hong Kong Institute of Biotechnology
The Jackson Laboratory
The Jenner Institute
The Michael J. Fox Foundation
The Native Antigen Company
The Pregene (ShenZhen) Biotechnology
University Hospital Tuebingen
The University of Queensland
The University of Tennessee Health Science Center
The Vector Core, University of North Carolina
Themis (acquired by Merck)
TheraBiologics
TheraVectys (subsidiary of the Pasteur Institute)
Thermo Fisher Scientific
Tianjin Mycure Medical Technology
Timmune Biotech
Tmunity Therapeutics
Tolerion
Touchlight
Transgene
Treadwell Therapeutics
Treeway
Trizell
Twist Bioscience
TxCell
UC Davis
UC San Diego School of Medicine
UK Cystic Fibrosis Gene Therapy Consortium
Ultragenyx Pharmaceutical
uniQure
UniverCells
University Medical Center Groningen
University of Adelaide
University of California
University of Eastern Finland
University of Florida
University of Iowa
University of Michigan Health
University of Minnesota
University of North Carolina
University of Pennsylvania
University of Pittsburgh
University of South Carolina School of Medicine
University of Southampton
University of Tennessee Health Science Center
University of Tokyo
University of Virginia School of Medicine
Urovant Sciences
USC School of Pharmacy
Vaccine Manufacturing and Innovation Centre (VMIC)
Vaccitech
VBL Therapeutics
VCN Biosciences
Vectalys
Vector Biolabs
Vecura
VGXI
Vibalogics
Vical
Vigene Biosciences
Vineti
ViralGEN
Virapur
ViraQuest
ViroMed
Virovek
Karolinska Institute
VIVEbiotech
Voyager Therapeutics
Wacker Biotech
Waisman Biomanufacturing
Washington University School of Medicine
Wellington Zhaotai Therapies
WhiteLab Genomics
Wuhan Bio-Raid Biotechnology
Wuhan Sian Medical Technology
WuXi AppTec
Wyvern Pharmaceuticals
Xiangxue Life Sciences
Xpress Biologics
XyloCor Therapeutics
Xyphos Biosciences
Yake Biotechnology
Yonsei University Health System
YPOSKESI
Yufan Biotechnologies
Ziopharm Oncology

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4712EUR$4,799USD£3,932GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6872EUR$6,999USD£5,734GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€17672EUR$17,999USD£14,746GBP

Scope of the Report

Amongst other elements, the report includes:

Key Questions Answered

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Viral Vectors and Plasmid DNA Global Market Report 2024

Gene Therapy Market, 6th Edition: Industry Trends and Global Forecasts to 2035 - Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Geographical Region, Leading Market Players and Sales Forecast

Viral Vector Manufacturing Global Market Report 2024

Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034

Viral Vector and Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report by Vector Type (AAV, Lentivirus), Workflow, Application, End-use, Disease, Region, and Segment Forecasts, 2024-2030